All In Biotech

Drug Trial Radar · NCT07097701

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR in Patients With Non-Dystrophic Myotonias (ACHILLES Study)

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 3, 2025

Primary completion

Jan 22, 2027

Study completion Feb 22, 2027

Sponsor

Lead sponsor
Lupin Ltd.Industry
Sponsor type
Industry
Collaborators
Lupin Atlantis Holdings S.A.
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)

Conditions

  • Myotonia

Interventions

  • Granular powder in unit dose foil-lined sachet Mexiletine (PR)Drug

    Mexiletine (PR)

  • Oral Capsule Mexiletine (IR)Drug

    Mexiletine (IR)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the safety of mexiletine PR vs mexiletine IR by incidence of treatment emergent Adverse Events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate between mexiletine PR and mexiletine IR after 12 weeks of treatment.Time frame: Baseline to week 24
  2. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QTc intervals by12-lead in ECGTime frame: Baseline to week 24
  3. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in PR intervals by12-lead in ECGTime frame: Baseline to week 24
  4. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QRS intervals by12-lead in ECGTime frame: Baseline to week 24
  5. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline by average minimum heart rate by12-lead in ECGTime frame: Baseline to week 24
  6. To compare the safety of mexiletine PR vs mexiletine IR by performing physical examiniationsTime frame: Baseline to week 24
  7. To compare the safety of mexiletine PR vs mexiletine IR by assessing vital signsTime frame: Baseline to week 24
  8. To compare the safety of mexiletine PR vs mexiletine IR by performing standard clinical laboratory evaluationsTime frame: Baseline to week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Leuven"UZ Leuven Gasthuisberg Campus Herestraat 49 Leuven, 3000"

    Leuven, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.